<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Leahy, Laura G.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Using Pharmacogenetics and Advanced Neuroscience to Personalize Treatment of Psychiatric Illness</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2-4</style></pages><abstract><style  face="normal" font="default" size="100%">In any given year, 26.2% of individuals in the United States experience a diagnosable psychiatric illness. Approximately 6% of adults suffer from a seriously debilitating mental illness. Among adolescents aged 13 to 18 years, 46.3% experience symptoms of psychiatric illness, and 21.4% experience a severe disorder. This article discusses clinical tools for personalizing psycho-pharmacologic treatment, including psychopharmacogenetics, laboratory studies, review of systems, symptom evaluation, and observation.</style></abstract><number><style face="normal" font="default" size="100%">44</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>